Trials / Conditions / OligoProgressive Metastatic Disease

OligoProgressive Metastatic Disease

11 registered clinical trials studyying OligoProgressive Metastatic Disease — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI) NCT06813664	University Health Network, Toronto	Phase 2
Recruiting	Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers NCT06918951	British Columbia Cancer Agency	N/A
Recruiting	Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study NCT06925984	Jules Bordet Institute	N/A
Recruiting	Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma NCT07112170	University Health Network, Toronto	N/A
Recruiting	Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogre NCT06841172	Shandong Cancer Hospital and Institute	Phase 3
Recruiting	Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer NCT06927635	University Health Network, Toronto	Phase 2
Active Not Recruiting	Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Ce NCT07076693	Shanghai Chest Hospital	Phase 2 / Phase 3
Recruiting	Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer NCT06601296	University of Texas Southwestern Medical Center	Phase 2
Recruiting	The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer NCT07038304	University Medical Center Groningen	Phase 2
Recruiting	Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer NCT06523673	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 3
Recruiting	A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for NCT06367972	M.D. Anderson Cancer Center	Phase 2 / Phase 3